New Investor

We are very pleased to announce the entry of a new investor into Lxbio Phar­ma­ceu­ti­cals S.A., rein­forc­ing the company’s momen­tum as it moves into its next phase of growth.
Found­ed in 2021, Lxbio Phar­ma­ceu­ti­cals is a Por­tuguese bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing high­ly inno­v­a­tive ther­a­peu­tic plat­forms to address major unmet med­ical needs, includ­ing infec­tious dis­eases, oncol­o­gy, and oth­er com­plex patholo­gies.
Our ambi­tion is clear: to trans­form cut­ting-edge sci­ence into tru­ly dif­fer­en­ti­at­ed, scal­able solu­tions with glob­al impact.
We proud­ly wel­come the funds Inno­va­tion, Research & Cre­ativ­i­ty (IRC) and Por­tu­gal Panora­ma Cap­i­tal as new share­hold­ers of Lxbio. Man­aged by Fund­Box, these funds have com­plet­ed their invest­ment at a €100 mil­lion com­pa­ny val­u­a­tion, reflect­ing strong con­fi­dence from the funds and their investors in Lxbio’s sci­en­tif­ic plat­forms, team, and exe­cu­tion capa­bil­i­ties.